Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
about
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsSitagliptin in the treatment of type 2 diabetes: a meta-analysis.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristicsNew-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.A review of the treatment of type 2 diabetes in childrenDipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioningInteractive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.Association between sitagliptin adherence and self-monitoring of blood glucose.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitusReview of sitagliptin phosphate: a novel treatment for type 2 diabetes.Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Vildagliptin: a review of its use in type 2 diabetes mellitus.Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV.Stability enhancement of drug layered pellets in a fixed dose combination tabletCombining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.Protective effect of sitagliptin and rosuvastatin combination on vascular endothelial dysfunction in type-2 diabetes.Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats.
P2860
Q24243196-9B79696F-8955-45E5-9922-6F0A06D7F8B9Q28081569-43B21DA6-6FBD-49B0-9317-C8135ED92D71Q34344570-C1E64620-C716-4F4D-B41C-A7AF2AA45B70Q34620693-F32C44CA-49F0-4F40-B77D-062F9BF1B821Q35100483-28530498-808C-462C-B8F3-BE5E388BD662Q35153309-1FFCFED0-188F-48EB-8B6C-8DF86E55DAC3Q35157954-94ADAEA4-DF92-49C4-BE4B-25432E36AD61Q35693453-ED2551E3-5601-4A4A-BB89-33804AADEC1AQ35833586-FE75319E-2795-4E30-89CE-A027B3DF514DQ36228968-1B557445-E3D8-465C-9A4C-B1D2DFB776D5Q36523423-730497C8-E01A-4538-B67C-2B5E06976441Q36854023-3AFE1F9F-DAB6-4D28-9A82-401E7AAFCBFEQ37176935-8D19A28F-6A0A-4AAC-98B9-ACE20EC91227Q37735838-CE397966-2048-44C5-8ABD-1C03A1102BE3Q37801906-B5744115-7AF6-4D99-80F3-3498DA8E913BQ40134994-37437BFD-6BF6-4925-97C7-912D5792AAFDQ41988061-CB07332B-1D00-47EC-97FE-157652B169ADQ42248942-C814B2A8-AA3C-4102-BC85-8C948461A7E5Q43182745-32AA5885-DDF9-4136-BD9D-BF78A4EE94D3Q44902330-95CF0A18-4490-4918-92AC-62D6456B34B0Q47830426-3C2DF7DC-789D-4450-B510-AB8D0CCBBB28
P2860
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@ast
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@en
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@nl
type
label
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@ast
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@en
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@nl
prefLabel
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@ast
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@en
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@nl
P2860
P356
P1476
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
@en
P2093
Erin L St Onge
Shannon Miller
P2860
P304
P356
10.1345/APH.1G665
P407
P577
2006-07-01T00:00:00Z